A recent study showed that inhibiting PCSK9 enhanced the antigen presentation efficacy of PD-1 and influenced the tumor response to immune checkpoint treatment, although through a mechanism unrelated to its role in controlling cholesterol (13, 14). This evidence concerns the gene PCSK9 and neoplasm.